Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2008-3-19
pubmed:abstractText
Epithelial-mesenchymal transition (EMT) has been considered to be involved in organ fibrogenesis. However, there is few direct evidence of this process in the pathophysiology of pulmonary fibrosis in vivo. Therefore, we tried to verify the involvement of this process in the development of pulmonary fibrosis. Since the co-expressions of epithelial and mesenchymal markers are thought to be a marker of EMT, we performed dual-immuunohistochemistry to assess the co-expressions of these proteins in lung tissues from bleomycin-induced pulmonary fibrosis in mice, and from patients with idiopathic pulmonary fibrosis, and nonspecific interstitial pneumonia. Double positive cells for epithelial markers including E-cadherin, T1alpha, or aquaporin 5, and a mesenchymal markers alpha-smooth muscle actin or vimentin were not found in bleomycin-induced pulmonary fibrosis in mice. Double positive cells for E-cadherin, ICAM-1, LEA, CD44v9, or SP-A and alpha-smooth muscle actin or vimentin were not found in lung tissues from normal lung parenchyma, idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. These results offer at least two possibilities. One is that EMT does not occur in IPF or bleomycin-induced pulmonary fibrosis in mice. Another is that EMT may occur in pulmonary fibrosis but the time during this transition in which cells express detectable levels of epithelial and mesenchymal markers is too small to be detected by double immunohistochemistry.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0948-6143
pubmed:author
pubmed:issnType
Print
pubmed:volume
129
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
453-62
pubmed:meshHeading
pubmed-meshheading:18236067-Actins, pubmed-meshheading:18236067-Adult, pubmed-meshheading:18236067-Aged, pubmed-meshheading:18236067-Animals, pubmed-meshheading:18236067-Antigens, CD44, pubmed-meshheading:18236067-Biological Markers, pubmed-meshheading:18236067-Bleomycin, pubmed-meshheading:18236067-Cadherins, pubmed-meshheading:18236067-Case-Control Studies, pubmed-meshheading:18236067-Disease Models, Animal, pubmed-meshheading:18236067-Epithelial Cells, pubmed-meshheading:18236067-Female, pubmed-meshheading:18236067-Humans, pubmed-meshheading:18236067-Immunohistochemistry, pubmed-meshheading:18236067-Lung Diseases, Interstitial, pubmed-meshheading:18236067-Male, pubmed-meshheading:18236067-Mesoderm, pubmed-meshheading:18236067-Mice, pubmed-meshheading:18236067-Middle Aged, pubmed-meshheading:18236067-Myocytes, Smooth Muscle, pubmed-meshheading:18236067-Pulmonary Fibrosis, pubmed-meshheading:18236067-Thoracoscopy, pubmed-meshheading:18236067-Vimentin
pubmed:year
2008
pubmed:articleTitle
Dual-immunohistochemistry provides little evidence for epithelial-mesenchymal transition in pulmonary fibrosis.
pubmed:affiliation
Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't